Neil S. Horowitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil S. Horowitz has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Charles W. Drescher
1 shared publication- David E. Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
1 shared publication David G Mutch
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington School of Medicine, St. Louis, Missouri, 63110
1 shared publicationJanet S Rader
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington School of Medicine, St. Louis, Missouri, 63110
1 shared publicationMary Atwood
1 shared publicationMatthew A. Powell
1 shared publication
Latest Publications
- 31 December 2003
- Published by Elsevier in Gynecologic Oncology
- Vol. 91 (3) , 658
Reply
- 1 July 2002
- Published by Elsevier in Gynecologic Oncology
- Vol. 86 (1) , 79-84
The Significance of Pneumatosis Intestinalis or Bowel Perforation in Patients with Gynecologic Malignancies
- 1 July 2002
- Published by Elsevier in Gynecologic Oncology
- Vol. 86 (1) , 79-84
The Significance of Pneumatosis Intestinalis or Bowel Perforation in Patients with Gynecologic Malignancies
- 1 February 2002
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 99 (2) , 235-240
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma
To evaluate the efficacy of high dose rate vaginal brachytherapy in the treatment of International Federation of Gynecology and Obstetrics stage IB, IC, and II endometrial carcinoma after surgical staging and complete lymphadenectomy. All patients with stage IB, IC, or II adenocarcinoma or adenosquamous carcinoma of the endometrium who received postoperative high dose rate vaginal brachytherapy at our institution between June 1, 1989, and June 1, 1999, were eligible. High dose rate vaginal brachytherapy was delivered in three fractions of 700 cGy. Retrospective chart review was performed. Kaplan-Meier estimates were calculated for disease-free and overall survival. One hundred sixty-four women were identified. Fifty-six percent had stage IB disease, 30% had stage IC disease, and 14% had stage II disease. Approximately one third of patients had high-grade lesions and nearly 40% had deep myometrial invasion. Median follow-up was 65 months (range 6-142 months). To date, 14 patients have had recurrence; 2 at the vaginal apex, 9 at distant sites, 1 at the pelvic sidewall, 1 simultaneously in the pelvis and at a distant site, and 1 at an unknown site. Both patients with vaginal apex recurrences had salvage therapy and are now free of disease. The overall 5-year survival and disease-free survival rates were 87% and 90%, respectively. There were no Radiation Therapy Oncology Group grade 3 or 4 toxicities. High dose rate vaginal brachytherapy was approximately $1,000 less expensive than external-beam whole-pelvic radiation. Adjuvant high dose rate vaginal brachytherapy in thoroughly staged patients with intermediate-risk endometrial carcinoma provides excellent overall and disease-free survival with less toxicity and at less cost compared with whole-pelvic radiation.
- 1 February 2002
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 99 (2) , 235-240
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma
To evaluate the efficacy of high dose rate vaginal brachytherapy in the treatment of International Federation of Gynecology and Obstetrics stage IB, IC, and II endometrial carcinoma after surgical staging and complete lymphadenectomy. All patients with stage IB, IC, or II adenocarcinoma or adenosquamous carcinoma of the endometrium who received postoperative high dose rate vaginal brachytherapy at our institution between June 1, 1989, and June 1, 1999, were eligible. High dose rate vaginal brachytherapy was delivered in three fractions of 700 cGy. Retrospective chart review was performed. Kaplan-Meier estimates were calculated for disease-free and overall survival. One hundred sixty-four women were identified. Fifty-six percent had stage IB disease, 30% had stage IC disease, and 14% had stage II disease. Approximately one third of patients had high-grade lesions and nearly 40% had deep myometrial invasion. Median follow-up was 65 months (range 6-142 months). To date, 14 patients have had recurrence; 2 at the vaginal apex, 9 at distant sites, 1 at the pelvic sidewall, 1 simultaneously in the pelvis and at a distant site, and 1 at an unknown site. Both patients with vaginal apex recurrences had salvage therapy and are now free of disease. The overall 5-year survival and disease-free survival rates were 87% and 90%, respectively. There were no Radiation Therapy Oncology Group grade 3 or 4 toxicities. High dose rate vaginal brachytherapy was approximately $1,000 less expensive than external-beam whole-pelvic radiation. Adjuvant high dose rate vaginal brachytherapy in thoroughly staged patients with intermediate-risk endometrial carcinoma provides excellent overall and disease-free survival with less toxicity and at less cost compared with whole-pelvic radiation.